ArticleAnnals of hematology2021

Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.

Heiner Zimmermann et al.PubMed ↗Publisher ↗

No numbers read from the abstract.